Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012–2014, a retrospective analysis

Health Policy

Volumn 120, Issue 11, 2016, Pages 1240-1248

  Kawalec, Paweł ^a   Malinowski, Krzysztof Piotr ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

AOTMiT; Health Technology Assessment; Ministry of Health; Polish Agency for Health Technology Assessment and Tariff System; Reimbursement system

Indexed keywords

ORPHAN DRUG;

ADVISORY COMMITTEE; ARTICLE; DECISION MAKING; DRUG PROGRAM; POLAND; PROTOCOL COMPLIANCE; PUBLIC HEALTH SERVICE; REIMBURSEMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK MANAGEMENT; BIOMEDICAL TECHNOLOGY ASSESSMENT; ECONOMICS; HEALTH CARE POLICY; HUMAN;

DECISION MAKING; HEALTH POLICY; HUMANS; POLAND; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85001115579     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2016.09.021     Document Type: Article

References (31)

1. [1] The Agency for Health Technology Assessment and Tariff System (AOTMiT). http://www.aotm.gov.pl/www/index.php?id=397.
2. [2] Ministry of Health Republic of Poland. http://www.mz.gov.pl/en.
3. [3] Prząda-Machno, P., Czech, M., The overview of Agency for Health Technology Assessment recommendationsin 2012, and their impact on reimbursement decisions. JHPOR 2 (2014), 12–17, 10.7365/JHPOR.2014.2.2.
4. [4] Lexchin, J., Mintzes, B., Medicine reimbursement recommendations in Canada, Australia, and Scotland. American Journal of Managed Care 14:9 (2008), 581–588.
5. [5] Bae, G., Bae, E.Y., Bae, S., Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea. Health Policy 119:5 (2015), 577–587.
6. [6] Mauskopf, J., Chirila, C., Birt, J., Boye, K.S., Bowman, L., Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?. Health Policy 110:1 (2013), 49–59.
7. [7] Iskrov, G., Stefanov, R., Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs: Research and Reviews 4 (2014), 1–9.
8. [8] Recommendation no 108/2012 of the President of AOTMiT issued on 12-Nov-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/085/REK/RP_108_2012_Levetiracetam.pdf.
9. [9] Recommendation no 109/2012 of the President of AOTMiT issued on 12-Nov-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/085/REK/RP_109_2012_Levetiracetam.pdf.
10. [10] Recommendation no 110/2012 of the President of AOTMiT issued on 12-Nov-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/085/REK/RP_110_2012_Levetiracetam.pdf.
11. [11] Recommendation no 111/2012 of the President of AOTMiT issued on 12-Nov-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/085/REK/RP_111_2012_Levetiracetam.pdf.
12. [12] Recommendation no 112/2012 of the President of AOTMiT issued on 12-Nov-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/085/REK/RP_112_2012_Levetiracetam.pdf.
13. [13] Recommendation no 113/2012 of the President of AOTMiT issued on 12-Nov-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/085/REK/RP_113_2012_Levetiracetam.pdf.
14. [14] Recommendation no 114/2012 of the President of AOTMiT issued on 12-Nov-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/085/REK/RP_114_2012_Levetiracetam.pdf.
15. [15] Recommendation no 115/2012 of the President of AOTMiT issued on 12-Nov-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/085/REK/RP_115_2012_Levetiracetam.pdf.
16. [16] Recommendation no 7/2013 of the President of AOTMiT issued on 21-Jan-2013. http://aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/097/REK/RP_7_2013_Lewetiracetam.pdf.
17. [17] Recommendation no 72/2012 of the President of AOTMiT issued on 24-Sep-2012. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/041/REK/RP_72_2012_Tetmodis.pdf.
18. [18] Recommendation no 63/2012 of the President of AOTMiT issued on 10-Sep-2012. http://aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/066/REK/RP_63_2012_Sprycel.pdf.
19. [19] Recommendation no 65/2012 of the President of AOTMiT issued on 10-Sep-2012. http://aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/066/REK/RP_65_2012_Sprycel.pdf.
20. [20] Recommendation no 66/2012 of the President of AOTMiT issued on 10-Sep-2012. http://aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/066/REK/RP_66_2012_Sprycel.pdf.
21. [21] Recommendation no 67/2012 of the President of AOTMiT issued on 10-Sep-2012. http://aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/066/REK/RP_67_2012_Sprycel.pdf.
22. [22] Recommendation no 70/2012 of the President of AOTMiT issued on 17-Sep-2012. http://aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/068/REK/RP_70_2012_Synagis.pdf.
23. [23] Recommendation no 71/2012 of the President of AOTMiT issued on 17-Sep-2012. http://aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/068/REK/RP_71_2012_Synagis.pdf.
24. [24] Recommendation no 8/2013 of the President of AOTMiT issued on 28-Jan-2013. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/107/REK/RP_8_2013_Myozyme.pdf.
25. [25] Recommendation no 133/2013 of the President of AOTMiT issued on 30-Sep-2013. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2013/207/REK/RP_133_2013_Padolten.pdf.
26. [26] Recommendation no 182/2013 of the President of AOTMiT issued on 30-Dec-2013. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2013/325/REK/RP_182_2013_Mozobil_(plerixafor).pdf.
27. [27] Recommendation no 212/2014 of the President of AOTMiT issued on 8-Sep-2014. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2014/144/REK/RP_212_2014_Lantus.pdf.
28. [28] Recommendation no 215/2014 of the President of AOTMiT issued on 15-Sep-2014. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2014/176/REK/RP_215_2014_Levemir.pdf.
29. [29] Recommendation no 234/2014 of the President of AOTMiT issued on 3-Nov-2014. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2014/201/REK/RP_234_2014_Mabthera.pdf.
30. [30] Recommendation no 3/2015 of the President of AOTMiT issued on 16-Jan-2015. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2014/254/REK/RP_3_2015_Victrelis.pdf.
31. [31] Recommendation no 4/2015 of the President of AOTMiT issued oh 16-Jan-2015. http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2014/255/REK/RP_4_2015_Metformax.pdf.